TherapeuticsMD Inc 2025年季度报告

3 (Unaudited - in thousands)Three Months EndedMarch 31,2025 Net loss from continuing operations(636)Adjustments to reconcile net loss to net cash provided by (used in) continuing operating activities:Depreciation and amortization95Write-off of patents and trademarks88Share-based compensation23154Changes in operating assets and liabilities:Other assets502Prepaid and other current assets433 Cash and cash equivalents - continuing operations, beginning of period5,059Total cash and cash equivalents, end of period$5,745$The accompanying notes are an integral part of these condensed consolidated financial statements. 4 (Unaudited)1. Business, basis of presentation, new accounting standards and summary of significant accounting policies in this Quarterly Report on Form 10-Q (“10-Q Report”) as “TherapeuticsMD,” “we,” “our” and “us.” This 10-Q Report includestrademarks, trade names and service marks, such as TherapeuticsMD®, vitaMedMD®, BocaGreenMD®, IMVEXXY®, andBIJUVA®, which are protected under applicable intellectual property laws and are the property of, or licensed by or to, us. Solely forconvenience, trademarks, trade names and service marks referred to in this 10-Q Report may appear without the ®, TM or SM display of other parties’ trademarks, trade names or service marks to imply, and such use or display should not be construed to imply arelationship with, or endorsement or sponsorship of us by, these other parties. become a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations thatpossess commercial capabilities in the relevant territories. On December 30, 2022 (the “Closing Date”), we completed a transaction In a License Agreement, dated December 4, 2022, between TherapeuticsMD and Mayne Pharma (the “Mayne License Agreement”), we granted Mayne Pharma, on the Closing Date, (i) an exclusive, sublicensable, perpetual, irrevocable license to research, develop,register, manufacture, have manufactured, market, sell, use, and commercialize the Licensed Products in the United States and itspossessions and territories and (ii) an exclusive, sublicensable, perpetual, irrevocable license to manufacture, have manufactured,import and have imported the Licensed Products outside the United States for commercialization in the United States and itspossessions and territories. United States during a calendar year reach $300.0million. Further, Mayne Pharma will pay us royalties on net sales of all Products inthe United States at a royalty rate of8.0% on the first $80.0million in annual net sales and7.5% on annual net sales above $80.0million, subject to certain adjustments, for a period of20years following the Closing Date. The royalty rate will decrease to2.0% on aProduct-by-Product basis upon the earlier to occur of (i) the expiration or revocation of the last patent covering a Product and (ii) ageneric version of a Product launching in the United States. Mayne Pharma will pay us minimum annual royalties of $3.0million per a fully paid-up and royalty free license for the Licensed Products.5 States, including, with the Population Council’s consent, our exclusive license from the Population Council to commercializeANNOVERA (the “Transferred Assets”). cash payment of approximately $12.1million at closing for the acquisition of net working capital as determined in accordance with theTransaction Agreement and subject to certain adjustments, (iii) a cash payment of approximately $1.0million at closing for prepaidroyalties in connection with the Mayne License Agreement Amendment (as defined below) and (iv) the right to receive the contingentconsideration set forth in the Mayne License Agreement, as amended. The acquisition of net working capital was determined in On the Closing Date, TherapeuticsMD and Mayne Pharma entered into Amendment No. 1 to the Mayne License Agreement (the“Mayne License Agreement Amendment”). Pursuant to the Mayne License Agreement Amendment, Mayne Pharma agreed to pay usapproximately $1.0million in prepaid royalties on the Closing Date. The prepaid royalties reduced the first four quarterly payments payment was paid to us. We and Mayne Pharma settled the $1.5million of consideration due to Mayne Pharma for the assumedobligations under a long-term services agreement, including our minimum payment obligations thereunder. As the parties agreed,during the second quarter of 2023 Mayne Pharma held back our royalty payment of $0.6million and we funded an additional $0.9 As part of the transformation that included the Mayne License Agreement, all results associated with former commercial operationshave been reflected as discontinued operations in our condensed consolidated financial statements. Assets and liabilities associated We also have license agreements with strategic partners to commercialize IMVEXXY and BIJUVA outside of the U.S.●In July 2018, we entered into a license and supply agreement (the “Knight License Agreement”) with K